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Abstract
Background:  Gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples
represents a valuable approach for advancing oncology diagnostics and enhancing retrospective
clinical studies; however, at present, this methodology still requires optimization and thus has not
been extensively used. Here, we utilized thorough quality control methods to assess RNA
extracted from FFPE samples and then compared it to RNA extracted from matched fresh-frozen
(FF) counterparts. We preformed genome-wide expression profiling of FF and FFPE ovarian serous
adenocarcinoma sample pairs and compared their gene signatures to normal ovary samples.
Methods: RNA from FFPE samples was extracted using two different methods, Ambion and
Agencourt, and its quality was determined by profiling starting total RNA on Bioanalyzer and by
amplifying increasing size fragments of beta actin (ACTB) and claudin 3 (CLDN3) by reverse-
transcriptase polymerase chain reaction. Five matched FF and FFPE ovarian serous adenocarcinoma
samples, as well as a set of normal ovary samples, were profiled using whole genome Agilent
microarrays. Reproducibility of the FF and FFPE replicates was measured using Pearson correlation,
whereas comparison between the FF and FFPE samples was done using a Z-score analysis.
Results: Data analysis showed high reproducibility of expression within each FF and FFPE method,
whereas matched FF and FFPE pairs demonstrated lower similarity, emphasizing an inherent
difference between the two sample types. Z-score analysis of matched FF and FFPE samples
revealed good concordance of top 100 differentially expressed genes with the highest correlation
of 0.84. Genes characteristic of ovarian serous adenocarcinoma, including a well known marker
CLDN3, as well as potentially some novel markers, were identified by comparing gene expression
profiles of ovarian adenocarcinoma to those of normal ovary.
Conclusion: Conclusively, we showed that systematic assessment of FFPE samples at the RNA
level is essential for obtaining good quality gene expression microarray data. We also demonstrated
that profiling of not only FF but also of FFPE samples can be successfully used to identify
differentially expressed genes characteristic of ovarian carcinoma.
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Background
According to the American Cancer Society, ovarian cancer
is the fifth leading cause of cancer deaths in women in the
United States. The most common, epithelial, type of ovar-
ian cancer can be divided into several subtypes including:
serous, endometrioid, mucinous, clear cell and undiffer-
entiated. Serous adenocarcinoma comprises majority of
cases and exhibits a poor 5-year survival rate. Up to 90%
of ovarian cancers might be cured if identified in an early
stage. When diagnosed in later stages, the rate drops sig-
nificantly to a range of 30–50%. Detection of ovarian can-
cer is often delayed or missed because of a lack of clear
symptoms and absence of reliable diagnostic methods.
Cancer marker 125 (CA125), the product of mucin 16, is
currently used for testing patients with elevated risk of
ovarian cancer. However, this marker alone does not pro-
vide the required sensitivity or specificity to detect all
cases [1]. Another gene, claudin 3 (CLDN3), has been
found to be highly expressed at gene and protein levels
and thus has been suggested as a reliable marker of ovar-
ian cancer [2-5].
Large repositories of formalin-fixed, paraffin-embedded
(FFPE) samples are available and could be used to identify
markers for diagnosis of many diseases. While tissue
integrity in FFPE specimens is often better preserved than
in matched fresh-frozen (FF) counterparts, the quality of
nucleic acids in FFPE samples is far from optimal due to
chemical crosslinking and nucleic acid fragmentation [6-
8]. Despite the detrimental effect of the fixative, numerous
studies using archived FFPE samples have generated satis-
factory reverse-transcriptase polymerase chain reaction
(RT-PCR) data [9-13]. Recently, a number of genome-
wide microarray studies has been conducted to investigate
gene expression in FFPE samples or to compare the per-
formance of FFPE samples with their matched FF counter-
parts [14-23]. While the results of some studies are
discouraging [16,19], many archived FFPE samples have
been successfully used to identify prognostic and diagnos-
tic gene signatures for numerous diseases, including vari-
ous carcinomas [21-24].
Methods
Samples
Matched FF and FFPE samples were obtained from five
ovarian serous adenocarcinoma patients. Samples 3136,
3138, 3194 and 3207 were collected on 11/2004, 11/
2004, 05/2005, and 06/2005, respectively. A portion of
each sample was either frozen at -80°C until extraction or
fixed within 30 minutes of surgery by incubation in 10%
neutral-buffered formalin (NBF) for 4–18 hours at 4°C.
Patient sample 390 was collected on 01/2005 and was
either frozen or fixed for 24 hours at room temperature in
10% NBF within 30 minutes of surgery. Only tumor sam-
ples containing minimal necrosis (<10%) and consisting
of 70% or more tumor cells were used in this study. A set
of normal ovary samples was obtained from different
patients by dissecting normal tissue adjacent to tumors.
All tumor and normal ovary samples were acquired com-
mercially by the Human Tissue Lab at Genentech.
RNA extraction methods
FF samples
Three 10-micron sections were homogenized individually
and RNA was extracted using the RNeasy Lipid Tissue
Mini Kit (Qiagen, San Diego, CA). Replicate RNA preps
were pooled to obtain sufficient amounts of starting mate-
rial. For normal ovary samples, RNA was extracted using
Qiagen's ALLPrep method that included on-column
DNase treatment.
FFPE samples
After evaluating four FFPE RNA extraction methods (Inv-
itrogen PureLink, Ambion RecoverAll, Ambion Optimum
and Agencourt FormaPure; data not shown), the Opti-
mum FFPE RNA Isolation Kit (Ambion, Austin, TX) and
the FormaPure Kit (Agencourt, Beverly, MA) were selected
for this study based on their potential to generate the most
abundant population of high molecular weight RNA frag-
ments. The two methods were used to extract RNA from
five archived FFPE ovarian serous adenocarcinoma sam-
ples. Up to eight 10-micron FFPE sections were processed
per patient. Ambion's RNA extraction procedure was opti-
mized for maximum RNA recovery (Susanna Stinson,
Genentech, Inc., personal communication) by elevating
the temperature of the first 10 min deparaffinization to
55°C and digesting the samples for 3 hours at 55°C. After
adding a fresh aliquot of Proteinase K, the samples were
digested for an additional hour at 55°C. The Agencourt
protocol was followed without any modifications. DNase
treatment was applied to both FF and FFPE samples and
was followed by phenol:chloroform:isoamyl alcohol
purification and ethanol precipitation.
Quality control methods
The quantity of RNA and labeled cRNA was measured
using Nanodrop ND-1000 UV-spectrophotometer (Nano-
Drop Technologies, Wilmington, DE). Specific activity of
cRNA, calculated as picomoles of Cy5 dye per microgram
(μg) of cRNA, was also measured by Nanodrop. Sample
integrity was evaluated by profiling both RNA and cRNA
on Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA).
RNA integrity was determined by amplifying different
length fragments (~200, 400, 600 and 800 basepairs (bp))
of beta actin (ACTB) and CLDN3 genes using Qiagen's
OneStep RT-PCR kit protocol. The following 5'-3' primers
were used to amplify ACTB [GenBank:NM_001101]: 200
F GGTGATAGCATTGCTTTCGTGTAA, 400 F CAGTCG-BMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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GTTGGAGCGAGCATCC, 600 F CTCCATCGTCCACCG-
CAAATGC, 800 F GGCACCACCATGTACCCTGGCA and
R TCAAGTCAGTGTACAGGTAAGCC. The following 5'-3'
primers were used to amplify CLDN3  [GenBank:
NM_001306]: 200 F CCATCCAGCGTGCAGCCTTGC,
400 F GCTGCTCTGCTGCTCGTGTCC, 600 F CCAAGAT-
CACCATCGTGGCAGG, 800 F GCCTGTGGATGAACT-
GCGTGG and R AGTATTGGCGGTCACCCAGGC. Five
nanograms of RNA were used as a template for reverse
transcription (30 min at 50°C), followed by activation of
the HotStarTaq polymerase (15 min at 95°C), 35 cycles of
PCR (30 sec at 95°C, 30 sec at 60°C, and 1 min at 72°C),
and final 10 min extension at 72°C. Each fragment was
amplified individually; however, all of them were pooled
and electrophoresed in a single lane. PCR products were
visualized on 4% agarose e-gels (Invitrogen, Carlsbad,
CA). SimplyLoad 100 bp DNA Ladder (Lonza, Basel, Swit-
zerland) was used to determine product size.
Microarrays
Total RNA was labeled according to Agilent's Low RNA
Input Fluorescent Linear Amplification Kit. The test sam-
ples (i.e. RNA from FF and FFPE samples) were labeled
with the Cy5 dye and the reference sample (i.e. Universal
Human Reference, Stratagene, La Jolla, CA) was labeled
with the Cy3 dye. Matched FF samples (5 patients, 2 rep-
licates) and FFPE samples extracted using either the Agen-
court method (5 patients, 3 replicates for 3136, 3138 and
3194, 2 replicates for 3207 and 390) or the Ambion
method (5 patients, no replicates) were hybridized to Agi-
lent Whole Human Genome 4×44K microarrays accord-
ing to the manufacturer's protocol. Microarray images
were analyzed using Agilent's Feature Extraction (FE) soft-
ware, version 9.5.
Data analysis
Reproducibility of the FF and FFPE sample types was
measured using Pearson correlations (r). Only "passing"
probes were included in this analysis, where "passing"
consisted of probes that were not recognized as outliers by
the FE software, were significantly above background, and
had a P value of the Cy5/Cy3 ratio below 0.05. We com-
pared results between sample types (frozen versus fixed)
by applying a Z-score analysis [25] to the four samples
whose quality was adequate for microarray profiling
(3136, 3138, 3194, and 3207). For small data sets, the Z-
score technique provides a method for determining genes
that have significantly different expression in a single sam-
ple relative to other samples. These scores indicate the
degree of deviation from the mean, in terms of the
number of standard deviations, and they are likely to
reveal well-behaving probes because they impose two
requirements: a large deviation in one sample compared
to the remaining samples, indicating a likely true biologi-
cal difference in expression, and a small standard error,
indicating that the probe set gives consistent measure-
ments in the remaining n-1 samples. Before the Z-score
analyses were applied, we computed geometric means of
relevant replicate measurements for the two groups: FF
tumor (4 patients, excluding sample 390) and FFPE-Agen-
court tumor (4 patients, excluding sample 390). FFPE-
Ambion tumor samples were not included in the Z-score
analysis. We then computed Z-scores for each FFPE sam-
ple relative to the remaining three FFPE samples with a
constant factor of 1 added to the denominator to avoid
situations where the standard error was spuriously close
to zero. For comparison, we also computed Z-scores using
the same methodology for each of the FF samples relative
to the other three FF samples. We then evaluated three cri-
teria for filtering data from the FFPE samples. First, we
considered all probes assayed on the array. Second, we
considered only those probes where the Cy5 channel had
a value of 1000 or greater ("1000 Cy5"). Finally, we con-
sidered top 100 differentially expressed probes that were
both "1000 Cy5" and had the largest Z-scores, namely, the
top 50 positive and top 50 negative Z-scores ("100 DE").
For each matched pair, we compared the selected FFPE Z-
scores with corresponding FF Z-scores. Furthermore, for
each of these three criteria, we evaluated correlation both
quantitatively and qualitatively. The quantitative compar-
ison measured the Pearson correlations of the Z-scores
between the FFPE and FF samples. For the qualitative
comparison, we tallied the "100 DE" probes whose signs
of the FFPE Z-scores were the same as or opposite of the
corresponding FF scores. The reported misclassification
rates reflect the number of opposite-sign probes as a frac-
tion of the total 100 probes.
Identification of genes that were differentially expressed
in serous adenocarcinoma compared to normal ovary was
achieved by a stepwise analysis. First, probes "passing" in
all replicates of the four groups including FF, FFPE-Agen-
court, and FFPE-Ambion tumors (see replicate details
above) and FF normal samples (5 patients, 2 replicates per
patient) were selected. Replicate Cy5/Cy3 ratios for each
passing probe were averaged within a method before per-
forming the Cyber t-test [26]. This t-test compared Cy5/
Cy3 log10 ratios of FF tumor (n = 5) vs normal (n = 5) and
FFPE tumor (n = 4) vs normal (n = 5); only probes with P
values of equal to or less than 0.05 were considered fur-
ther. All patient samples within a method were then aver-
aged by calculating geometric means of the Cy5/Cy3
ratios for the genes that passed the two previous criteria
("passing" and t-test P value cutoff of 0.05). The resulting
tumor-to-normal ratios are reported, where the ratio is at
least 2-fold higher in all tumors than in all normals.
Results
Quality assessment of FF and FFPE samples
Following RNA quantification using Nanodrop, Agilent
2100 Bioanalyzer was utilized to generate RNA profiles
for all FF and FFPE matched pairs (Figure 1A). FF samplesBMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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showed high quality of RNA; 18S and 28S ribosomal
peaks were present in all samples giving RNA Integrity
Numbers (RINs) from 6.5 to 8.5. In contrast, the land-
mark ribosomal peaks were not detected in any of the
FFPE samples, resulting in lower RINs. Since RINs depend
on the presence of ribosomal peaks in the RNA samples,
they can not accurately reflect the quality of FFPE RNA.
For example, the most degraded sample 390 showed the
highest RINs among all FFPE samples. RNA profiles
obtained from the FFPE samples were similar for the two
RNA extraction methods. FFPE samples 3138, 3194, and
3207 exhibited desirable profiles with elevated levels of
high molecular weight RNAs. In contrast, small molecular
weight RNAs were recognized as a sharp peak between 25
and 200 nucleotides (nt); the peak was the most promi-
nent feature in samples 3136 and 390. Closer comparison
between these two samples revealed that sample 3136
contained relatively low level of high molecular weight
RNA fragments, while a flat electropherogram beyond
500 nt suggests absence of such RNA fragments in sample
390. Based on these results, FFPE sample 390 was classi-
fied as having inadequate RNA quality; this was surprising
since slide examination indicated that it contained well
preserved tissue.
Additional quality assessment of total RNA obtained from
matched FF and FFPE samples was done by RT-PCR
amplification of different length fragments of ACTB and
CLDN3 genes. As expected, RNA from FF samples resulted
in amplification of all fragment sizes (Figure 2). The larg-
est amplicon, 800 bp, was observed only in FF samples,
suggesting that intact RNA of such length was rare in FFPE
samples. RNA extracted from FFPE sample 390 failed to
produce any ACTB  and  CLDN3  fragments (data not
Bioanalyzer profiles of total RNA (A) and cRNA (B) of matched FF and FFPE ovarian serous adenocarcinoma samples 3136,  3138, 3194, 3207 and 390 Figure 1
Bioanalyzer profiles of total RNA (A) and cRNA (B) of matched FF and FFPE ovarian serous adenocarcinoma 
samples 3136, 3138, 3194, 3207 and 390. The method used for RNA extraction (Qiagen, Agencourt, Ambion) is indicated 
for each sample type. The RNA Integrity Number (RIN) is shown next to each total RNA profile.
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shown). For the remaining four FFPE samples, amplifica-
tion of 200 bp, 400 bp and 600 bp fragments was
achieved for the ACTB  gene. For CLDN3, the 200 bp
amplicon was detected in four FFPE samples. The 400 bp
fragment was detected in two samples (3136 and 3138);
one additional sample that was processed with the
Ambion method (3194) showed weak presence of this
amplicon, suggesting that it may have more intact RNA
compared to the Agencourt counterpart. In contrast to
ACTB, CLDN3 amplicons >400 bp were not detected in
any of the FFPE samples.
cRNA yields from FF samples averaged at 12.5 μg, while
those from FFPE samples ranged from 2.2 to 6.1 μg. This
illustrates greater dependence of cRNA yield on RNA qual-
ity than on quantity since equal amounts of total RNA
were used to generate cRNAs. High specific activities rang-
ing from 10.9 to 13.6 pmol Cy5/μg were observed for
cRNAs from FF samples. The corresponding FFPE samples
resulted in noticeably lower specific activities ranging
from 1.6 to 7.6 pmol Cy5/μg cRNA. FFPE sample 390 had
the lowest dye incorporation compared to all other sam-
ples: 1.6 and 2.4 pmol Cy5/μg cRNA for Agencourt and
Ambion, respectively. Based on this result, as well as on
poor RNA quality described above, FFPE sample 390 was
expected to perform poorly in subsequent expression pro-
filing.
Similar to the quality assessment of total RNA, labeled
cRNA was also examined on the 2100 Bioanalyzer (Figure
1B). The size distribution of cRNA was very different when
comparing electropherograms obtained from FF and FFPE
samples. In FF samples, cRNAs showed a wide profile
encompassing molecular weight size above 4000 nt, with
the highest frequency of fragments in ~200 nt range. In
contrast, cRNAs generated from FFPE samples had narrow
profiles of up to ~1000 nt, with the highest frequency of
fragments in ~100 nt range. Similar to the initial total
RNA profile, cRNA for sample 390 showed a very narrow
distribution range and lacked fragments above ~500 nt.
Gene expression profiling
Reproducibility of genome-wide expression profiling of
FF and FFPE samples was calculated using Pearson corre-
lations (r). As shown in Figure 3, high reproducibility
across replicates was observed regardless of the sample
type. The r value for "passing" probes (see Methods)
ranged from 0.988 to 0.991 within FF replicates and from
0.983 to 0.985 within FFPE replicates. Although both FF
and FFPE samples displayed similar r values, scatter
graphs obtained by plotting log2 ratio values of FF repli-
cates appeared tighter compared to the FFPE replicates.
The lowest number of passing probes was observed in
FFPE sample 390; this was not surprising since this sample
was classified as inadequate for expression profiling based
on the quality of RNA and cRNA. Thus, sample 390 was
not taken into account in subsequent analyses.
Z-score analysis was used to determine the level of con-
cordance between matched FF and FFPE-Agencourt sam-
ples. As shown in Figure 4A, the three selection criteria
showed progressively increasing correlations and decreas-
RT-PCR amplification of different fragment sizes (200, 400, 600 and 800 bp) of ACTB and CLDN3 genes in FF and matched FFPE  ovarian adenocarcinoma samples 3136, 3138, 3194, and 3207 Figure 2
RT-PCR amplification of different fragment sizes (200, 400, 600 and 800 bp) of ACTB and CLDN3 genes in FF 
and matched FFPE ovarian adenocarcinoma samples 3136, 3138, 3194, and 3207. The method used for RNA 
extraction is indicated next to each sample type.
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ing misclassification rates, with the "100 DE" criterion
achieving the best concordance. Sample 3138 showed the
lowest concordance between its FF and FFPE z-scores,
achieving a correlation of 0.553 and misclassification rate
of 33%. However, the remaining samples showed rela-
tively high correlations ranging from 0.743 to 0.837 and
misclassification rates of 2–15%. The scatter plots of FF
and FFPE Z-scores (Figure 4B) indicate that the three filter-
ing criteria place tighter bounds on the analyses and the Z-
scores for probe sets obtained under the "1000 Cy5" and
"100 DE" criteria fall close to the diagonal axes. These two
criteria also produce qualitatively better results with the
differentially expressed probes found predominantly in
the first and third quadrants of the plots.
Microarray gene expression profiles from ovarian tumor
samples were also compared to those of normal ovary tis-
sue. The analysis of four patient samples, including FF as
well as FFPE samples processed by the Ambion and Agen-
court methods, identified 56 genes whose expression was
at least two-fold higher in tumor than in normal ovary.
Table 1 lists tumor-to-normal ratios obtained from the FF
and FFPE-Agencourt samples. Thirty three out of these 56
genes have been previously associated with various can-
cers and include cell cycle regulatory genes CDC6 [27],
CDT1 [28] and DTL [29]. A well known marker of ovarian
serous carcinoma, CLDN3, appeared at the top of the list.
In contrast, the probe for CA125 was not classified as
"passing" in all of the samples and thus it is not included
in the list. Several other genes, including TACSTD1 [3],
PRAME [30] and ERBB4 [31], have been linked to ovarian
tumorigenesis. PAX8 has been recently reported as a use-
ful marker for the differentiation between ovarian and
metastasized breast carcinoma [32]. Finally, the remain-
ing genes that we identified as overexpressed in tumor
samples may potentially represent some novel markers of
ovarian cancer.
Discussion
FFPE samples are a desirable source of archival material
for gene expression profiling studies due to their availabil-
ity and the possibility of retrospective studies. At present,
great variability is still being observed between gene
expression profiles of matched FF and FFPE samples. Sam-
ple source and its classification, as well as the conditions
used to fix and store samples, are some of many possible
variables influencing gene expression. For example, a
study relying on controlled fixation conditions to process
bone marrow cells reported that FFPE samples appeared
very similar to those of unfixed frozen equivalents [14].
However, controlled fixation procedure and use of cells
may not represent an optimal approach to demonstrate
the performance of archived FFPE tissue samples. Unsur-
prisingly, we have previously observed that FFPE cell pel-
lets dissociated faster during Proteinase K digestion and
often resulted in better RNA quality compared to FFPE tis-
sues.
FFPE samples are routinely prepared by fixing tissues in
10% neutral-buffered formalin for 12 to 24 hours at
ambient temperature. The FFPE samples used in this
study, except for sample 390, were fixed in formalin for 4
to 18 hours at 4°C. These samples appear to perform bet-
ter than sample 390 which was fixed using routine condi-
tions. Thus, it appears that shorter time and lower
temperature of fixation can significantly affect FFPE sam-
ple quality. Other variables such as size of collected tissue,
time elapsed to fixation and storage time could have fur-
ther affected this outcome [33,34]. Regarding storage
time, we have noticed that ribosomal RNA peaks could be
detected in FFPE samples that were stored properly for up
to one year and not for longer periods of time (data not
shown).
Two commercially available FFPE RNA isolation kits,
Ambion Optimum and Agencourt FormaPure, were tested
here for extracting RNA from five FFPE ovarian serous ade-
nocarcinoma samples. Sufficient amounts of total RNA
for gene expression profiling were achieved by processing
two to eight FFPE sections per patient. Despite pooling
multiple sections, the RNA yields from FFPE samples were
always significantly lower compared to those obtained
from FF samples (data not shown). In addition, the
obtained RNA amount was not proportional to the sur-
face area of tissues used for RNA extraction. Although sig-
nificant necrosis was not detected in any of the sections,
we noticed differences in tissue density and composition.
For example, presence of vasculature and adipose was
detected in some sections and undoubtedly affected the
Reproducibility of gene expression profiling within FF and  FFPE sample type Figure 3
Reproducibility of gene expression profiling within FF 
and FFPE sample type. Pearson correlation value (r) and 
number of "passing" probes are listed for samples 3136, 
3138, 3194, 3207 and 390. Scatter graphs of log2 ratios com-
paring two FF (top) and two FFPE replicates (bottom) are 
shown for sample 3194.BMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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amounts of recovered nucleic acids. With respect to tissue
content, all FFPE samples used in this study were required
to contain 70–85% tumor cells, ensuring that they truly
represented ovarian serous adenocarcinomas.
Two quality control assays, the Agilent 2100 Bioanalyzer
and RT-PCR, were employed to assess the integrity of RNA
obtained from FF and FFPE samples. Although RNA pro-
files from FFPE samples lacked well defined 18S and 28S
ribosomal peaks, the method was successful in identifying
inadequate samples, such as sample 390, containing pre-
dominantly small molecular weight fragments (<200 nt).
Our RT-PCR assay tested the RNA for the presence of dif-
ferent size fragments of two genes, ACTB and CLDN3. Not
surprisingly, we were not able to amplify any fragments in
FFPE sample 390. Thus, the data synergy observed
between the Bioanalyzer and the RT-PCR assay proved to
be very useful in qualifying FFPE samples suitable for gene
expression profiling on microarrays. These two assays also
demonstrated that both the Ambion Optimum and the
Agencourt FormaPure methods were successful in obtain-
ing RNA of similar quality. Together, the combination of
quality control methods used here should be effective in
recognizing poor-performing FFPE samples and could be
used to prevent unnecessary array hybridizations. A differ-
ent method for identifying unacceptable FFPE samples
has been described by NuGEN Technologies [35].
Gene expression profiling data of ovarian tumors demon-
strated high correlations between replicate FF (≥0.988)
and FFPE samples (≥0.983), illustrating good reproduci-
bility of each method. Although reproducible, gene
expression profiling of FFPE samples is affected by
reduced number of "passing" probes (33–46% compared
to 44–49% in FF) and thus detects fewer differentially
expressed genes compared to FF samples. Lassmann et al.
recently reported similar findings by detecting 36% and
50% of probes for FFPE and FF samples, respectively [20].
Our comparison between FF and their matched FFPE sam-
ples revealed the highest concordance of 0.84 for sample
3194. Although not directly comparable, a mean concord-
ance of 0.86 was reported previously when comparing
matched FF and FFPE samples on a different microarray
platform [17]. Haque et al. reported a correlation of 0.65
between unmatched FF and FFPE pediatric glioblastomas
[23]. While the magnitude of differential expression in
FFPE samples might not be accurate, our Z-score analysis
indicated that the direction of the change was correct in
most cases, as demonstrated by low misclassification
rates.
The comparison of ovarian serous adenocarcinoma to
normal ovary identified 56 genes that are overexpressed in
both FF and FFPE tumor samples. Several genes among
them, including CLDN3, were previously recognized for
their roles in ovarian tumorigenesis, [2-5,30-32]; addi-
tional genes with unknown roles were also identified. Pro-
filing of archival FFPE samples has been used previously
to identify gene signatures that may serve as prognostic
and diagnostic markers [20-24]. Regarding ovarian can-
cer, a set of 86 gene signatures that seems to predict overall
survival was recently identified by microarray profiling
[36]. Furthermore, 57 of these 86 genes were confirmed in
an independent dataset [37]. Together, these findings sug-
gest that archival FFPE samples can be successfully used to
identify potentially novel disease markers. At the same
time, it is recognized that gene expression profiling of
FFPE samples on microarrays has some limitations. In our
study, as well as in Van Deerlin et al. [38], the magnitude
of differential expression was typically higher in FFPE
than in FF samples, suggesting higher level of noise in the
FFPE data. Therefore, the elimination of false positives
and identification of subtle changes in gene expression in
FFPE samples remain challenging, especially in studies
lacking FF counterparts.
Technological improvements in handling FFPE samples
are constantly evolving; some of them clearly lead towards
better quality of microarray expression data. One such
improvement entails a change in primers used during
amplification. At present, commonly used procedures rely
on oligo (dT) primers which introduce 3' end bias
Z-score analyses comparing FFPE and FF samples Figure 4
Z-score analyses comparing FFPE and FF samples. 
Pearson correlation and misclassification rate (A) as well as 
scatter plots of Z-score values (B) for samples 3136, 3138, 
3194 and 3207 are shown for "All probes" (in grey), "1000 
Cy5" (in red) and "100 DE" (in blue) probe selection criteria.BMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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Table 1: List of genes whose ratios are at least two-fold higher in ovarian serous adenocarcinoma compared to normal ovary.
ProbeName GeneName Annotation FF tumor/FF normal ratio FFPE tumor/FF normal ratio
A_23_P91081 TACSTD1 tumor-associated calcium signal 
transducer 1 (TACSTD1), mRNA 
[NM_002354]
43.7 5.1
A_23_P118894 ATAD4 ATPase family, AAA domain containing 4 
(ATAD4), mRNA [NM_024320]
25.1 20.4
A_23_P71017 CLDN3 claudin 3 (CLDN3), mRNA 
[NM_001306]
20.4 77.2
A_23_P124335 THC2539702 Q9F8M7_CARHY (Q9F8M7) DTDP-
glucose 4,6-dehydratase (Fragment), 
[THC2546981]
20.0 22.2
A_24_P411186 BCL11A B-cell CLL/lymphoma 11A (zinc finger 
protein) (BCL11A), transcript variant 
1, mRNA [NM_022893]
18.7 14.8
A_24_P273647 LOC146439 mRNA; cDNA DKFZp666L166 (from clone 
DKFZp666L166). [AL833749]
17.5 95.5
A_23_P393051 C1orf172 chromosome 1 open reading frame 172 
(C1orf172), mRNA [NM_152365]
16.9 18.0
A_24_P153713 MARVELD3 MARVEL domain containing 3 
(MARVELD3), transcript variant 1, 
mRNA [NM_001017967]
14.4 34.7
A_24_P57977 SNIP SNAP25-interacting protein (SNIP), 
mRNA [NM_025248]
12.6 32.1
A_23_P83339 RNF183 ring finger protein 183 (RNF183), mRNA 
[NM_145051]
11.1 36.2
A_23_P50096 TYMS thymidylate synthetase (TYMS), 
mRNA [NM_001071]
11.1 3.0
A_23_P33511 AX721087 Incyte sequence 47 from Patent 
WO0220754. [AX721087]
11.0 23.4
A_23_P163481 BUB1B BUB1 budding uninhibited by 
benzimidazoles 1 homolog beta 
(yeast) (BUB1B), mRNA 
[NM_001211]
10.2 4.3
A_32_P57013 BU540282 AGENCOURT_10326456 NIH_MGC_141 
cDNA clone IMAGE:6571686 5', mRNA 
[BU540282]
10.0 105.4
A_23_P319859 EYA2 eyes absent homolog 2 (Drosophila) 
(EYA2), transcript variant 2, mRNA 
[NM_172113]
9.9 4.2
A_32_P183765 ERBB4 v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) (ERBB4), 
mRNA [NM_005235]
9.6 8.6
A_23_P385861 CDCA2 cell division cycle associated 2 
(CDCA2), mRNA [NM_152562]
9.4 6.8
A_32_P46456 THC2648851 glucosidase, beta (bile acid) 2 (GBA2), 
mRNA [NM_020944]
9.4 22.0
A_32_P30874 AJ420543 mRNA full length insert cDNA clone 
EUROIMAGE 1090207. [AJ420543]
9.3 30.6
A_24_P402588 BCL11A B-cell CLL/lymphoma 11A (zinc finger 
protein) (BCL11A), transcript variant 
1, mRNA [NM_022893]
9.2 31.1
A_23_P210001 PAX8 paired box gene 8 (PAX8), transcript 
variant PAX8A, mRNA [NM_003466]
8.4 31.3
A_32_P136033 AK090477 mRNA for FLJ00399 protein. [AK090477] 8.4 12.8
A_23_P166508 BC038245 clone IMAGE:5241654, mRNA. [BC038245] 7.9 9.1
A_23_P18579 PTTG2 pituitary tumor-transforming 2 
(PTTG2), mRNA [NM_006607]
7.5 7.8
A_23_P78958 CAPS calcyphosine (CAPS), transcript variant 1, 
mRNA [NM_004058]
7.2 11.1
A_23_P72411 CYP4X1 cytochrome P450, family 4, subfamily X, 
polypeptide 1 (CYP4X1), mRNA 
[NM_178033]
7.2 4.0
A_32_P151244 AK022268 cDNA FLJ12206 fis, clone 
MAMMA1000941. [AK022268]
7.0 22.2
A_23_P103851 DTL denticleless homolog (Drosophila) 
(DTL), mRNA [NM_016448]
6.5 5.4
A_23_P68669 CHODL chondrolectin (CHODL), mRNA 
[NM_024944]
6.4 9.6
A_32_P148745 FLJ14712 cDNA FLJ14712 fis, clone NT2RP3000825. 
[AK027618]
6.1 3.3
A_23_P151915 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin 
type. Acc:NP_004742] [ENST00000267857]
5.9 11.9
A_32_P77933 FLJ22795 colon cancer-associated antigen 
AgSK1-2HT-ECS mRNA, complete 
cds. [AF316855]
5.9 24.1BMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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A_23_P31073 MYB v-myb myeloblastosis viral oncogene 
homolog (avian) (MYB), mRNA 
[NM_005375]
5.5 24.8
A_23_P28953 DNMT3B DNA (cytosine-5-)-methyltransferase 
3 beta (DNMT3B), transcript variant 
6, mRNA [NM_175850]
5.3 8.9
A_32_P117186 CR749547 mRNA; cDNA DKFZp686J17110 (from 
clone DKFZp686J17110) [CR749547]
5.0 4.1
A_32_P128558 FLJ22795 colon cancer-associated antigen 
AgSK1-2HT-ECS mRNA, complete 
cds. [AF316855]
4.8 15.7
A_23_P166360 PRAME preferentially expressed antigen in 
melanoma (PRAME), transcript 
variant 5, mRNA [NM_206956]
4.5 3.1
A_23_P103720 AGMAT agmatine ureohydrolase (agmatinase) 
(AGMAT), mRNA [NM_024758]
4.3 2.8
A_23_P42935 BRAF v-raf murine sarcoma viral oncogene 
homolog B1 (BRAF), mRNA 
[NM_004333]
4.2 3.6
A_24_P741023 BC008476 cDNA clone IMAGE:4290767. [BC008476] 3.9 18.5
A_23_P49972 CDC6 cell division cycle 6 homolog (S. 
cerevisiae) (CDC6), mRNA 
[NM_001254]
3.9 4.7
A_24_P925191 THC2640472 Q2M1U4_HUMAN (Q2M1U4) Catalase, 
partial (31%) [THC2640472]
3.9 6.5
A_24_P145316 DTNBP1 dystrobrevin binding protein 1 
(DTNBP1), transcript variant 2, 
mRNA [NM_183040]
3.8 5.9
A_23_P19987 IGF2BP3 insulin-like growth factor 2 mRNA 
binding protein 3 (IGF2BP3), mRNA 
[NM_006547]
3.7 13.6
A_23_P1487681 F5 coagulation factor V (proaccelerin, labile 
factor) (F5), mRNA [NM_000130]
3.6 78.1
A_23_P37704 CDT1 chromatin licensing and DNA 
replication factor 1 (CDT1), mRNA 
[NM_030928]
3.5 7.5
A_24_P544543 CAPN1 cDNA FLJ12257 fis, clone 
MAMMA1001501, highly similar to 
CALPAIN 1. [AK022319]
3.1 8.2
A_23_P89570 ZMYND15 zinc finger, MYND-type containing 15 
(ZMYND15), mRNA [NM_032265]
2.9 11.8
A_24_P340659 AF268613 POU 5 domain protein (POU5FLC1) 
mRNA, complete cds. [AF268613]
2.8 3.1
A_24_P343095 DHFR dihydrofolate reductase (DHFR), 
mRNA [NM_000791]
2.8 2.6
A_24_P257099 DKFZp762E1312 hypothetical protein DKFZp762E1312 
(DKFZp762E1312), mRNA 
[NM_018410]
2.7 2.9
A_23_P110957 FOXF2 forkhead box F2 (FOXF2), mRNA 
[NM_001452]
2.7 3.9
A_23_P75260 RASSF4 Ras association (RalGDS/AF-6) 
domain family 4 (RASSF4), mRNA 
[NM_032023]
2.6 7.4
A_32_P81173 USP34 mRNA; cDNA DKFZp586J101 (from clone 
DKFZp586J101). [AL050376]
2.6 2.9
A_23_P156807 SDHAP3 succinate dehydrogenase complex, subunit 
A, flavoprotein pseudogene 3 (SDHAP3) 
[NR_003263]
2.6 9.5
A_23_P109072 SALL4 sal-like 4 (Drosophila) (SALL4), 
mRNA [NM_020436]
2.6 3.5
A_32_P132563 POU5F1 POU domain, class 5, transcription factor 1 
(POU5F1), transcript variant 1, mRNA 
[NM_002701]
2.5 10.8
A_23_P248701 CD44 CD44 molecule (Indian blood group) 
(CD44), transcript variant 1, mRNA 
[NM_000610]
2.5 5.2
Genes associated with cancer in previous reports are shown in bold. Fold change P≤0.05. Genes are sorted according to descending FF tumor/nomal ratios.
1Probe is represented on microarrays multiple times; average of multiple measurements is reported here.
Table 1: List of genes whose ratios are at least two-fold higher in ovarian serous adenocarcinoma compared to normal ovary. (Continued)BMC Medical Genomics 2009, 2:23 http://www.biomedcentral.com/1755-8794/2/23
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[17,39]; consequently, most commercial microarrays
have probes designed within the last several hundred
bases of each transcript. A new amplification procedure,
developed recently by NuGEN, utilizes random primers in
addition to oligo (dT) primers, thus alleviating the 3' end
bias. Initial studies suggest that such whole transcript
amplification provides a significant advantage when
processing FFPE samples [14,20]. Thus, this amplification
method deserves further investigation and holds promise
for improving the performance of FFPE samples in future
microarray profiling studies.
Conclusion
Five matched FFPE and FF ovarian tumor samples were
profiled on microarrays, illustrating the level of gene
expression similarity between the two sample types. Ovar-
ian tumor and normal samples were also compared, iden-
tifying a set of differentially expressed genes characteristic
of ovarian adenocarcinoma. Conclusively, our study dem-
onstrates that archived clinical samples, such as FFPE
ovarian adenocarcinomas, represent a valuable source for
genome-wide expression profiling and can be successfully
used for the identification of potentially novel carcinoma
markers. Further improvements in FFPE sample handling
and new amplification approaches hold promise for even
better performance of FFPE samples in future microarray
studies.
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